Connection
Halis Akturk to Antineoplastic Agents, Immunological
This is a "connection" page, showing publications Halis Akturk has written about Antineoplastic Agents, Immunological.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.110 |
|
|
|
-
Akturk HK, Couts KL, Baschal EE, Karakus KE, Van Gulick RJ, Turner JA, Pyle L, Robinson WA, Michels AW. Analysis of Human Leukocyte Antigen DR Alleles, Immune-Related Adverse Events, and Survival Associated With Immune Checkpoint Inhibitor Use Among Patients With Advanced Malignant Melanoma. JAMA Netw Open. 2022 12 01; 5(12):e2246400.
Score: 0.737
-
Akturk HK, Michels AW. Adverse events associated with immune checkpoint inhibitors: a new era in autoimmune diabetes. Curr Opin Endocrinol Diabetes Obes. 2020 08; 27(4):187-193.
Score: 0.627
-
Akturk HK, Michels AW. Immune Checkpoint Inhibitor-Induced Type 1 Diabetes: An Underestimated Risk. Mayo Clin Proc. 2020 03; 95(3):614-615.
Score: 0.609
-
Akturk HK, Alkanani A, Zhao Z, Yu L, Michels AW. PD-1 Inhibitor Immune-Related Adverse Events in Patients With Preexisting Endocrine Autoimmunity. J Clin Endocrinol Metab. 2018 10 01; 103(10):3589-3592.
Score: 0.138